CTLA4 and neoplasm: Indeed, Treg depletion and Fc receptor-dependent tumor rejection have been recently reported to play a major role for Ipilimumab and other anti-CTLA-4 antibodies with respect to checkpoint blockade dependent on B7-CTLA-4 interactions [42].